DE60036935T2 - Diagnostisches Verfahren für Eierstock- und Endometriumtumore basierend auf dem Nachweis des L1-Adhäsionsmoleküls - Google Patents

Diagnostisches Verfahren für Eierstock- und Endometriumtumore basierend auf dem Nachweis des L1-Adhäsionsmoleküls Download PDF

Info

Publication number
DE60036935T2
DE60036935T2 DE60036935T DE60036935T DE60036935T2 DE 60036935 T2 DE60036935 T2 DE 60036935T2 DE 60036935 T DE60036935 T DE 60036935T DE 60036935 T DE60036935 T DE 60036935T DE 60036935 T2 DE60036935 T2 DE 60036935T2
Authority
DE
Germany
Prior art keywords
antibody
ovarian
tumor
fragment
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60036935T
Other languages
German (de)
English (en)
Other versions
DE60036935D1 (de
Inventor
Peter Altevogt
Mina Fogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
German Cancer Research Center
Mor Research Applications Ltd
Original Assignee
German Cancer Research Center
Mor Research Applications Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by German Cancer Research Center, Mor Research Applications Ltd filed Critical German Cancer Research Center
Application granted granted Critical
Publication of DE60036935D1 publication Critical patent/DE60036935D1/de
Publication of DE60036935T2 publication Critical patent/DE60036935T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60036935T 2000-07-10 2000-07-10 Diagnostisches Verfahren für Eierstock- und Endometriumtumore basierend auf dem Nachweis des L1-Adhäsionsmoleküls Expired - Lifetime DE60036935T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00114788A EP1172654B1 (en) 2000-07-10 2000-07-10 Diagnostic method based on the detection of the L1 adhesion molecule for ovarian and endometrial tumors

Publications (2)

Publication Number Publication Date
DE60036935D1 DE60036935D1 (de) 2007-12-13
DE60036935T2 true DE60036935T2 (de) 2008-08-21

Family

ID=8169210

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60036935T Expired - Lifetime DE60036935T2 (de) 2000-07-10 2000-07-10 Diagnostisches Verfahren für Eierstock- und Endometriumtumore basierend auf dem Nachweis des L1-Adhäsionsmoleküls

Country Status (10)

Country Link
US (2) US7618785B2 (cg-RX-API-DMAC7.html)
EP (2) EP1172654B1 (cg-RX-API-DMAC7.html)
JP (1) JP5165827B2 (cg-RX-API-DMAC7.html)
CN (1) CN1479871A (cg-RX-API-DMAC7.html)
AT (1) ATE377192T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001285820A1 (cg-RX-API-DMAC7.html)
CA (1) CA2415364C (cg-RX-API-DMAC7.html)
DE (1) DE60036935T2 (cg-RX-API-DMAC7.html)
ES (1) ES2296586T3 (cg-RX-API-DMAC7.html)
WO (1) WO2002004952A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2296586T3 (es) * 2000-07-10 2008-05-01 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Metodo de diagnostico basado en la deteccion de la molecula de adhesion l1 para tumores de ovario y el endometrio.
US6852874B2 (en) 2000-10-02 2005-02-08 The Scripps Research Institute Second cycle asymmetric dihydroxylation reaction
EP1623995A1 (en) 2004-08-06 2006-02-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibitors of L1 and ADAM10 for the treatment of carcinomas
WO2007114550A1 (en) * 2006-04-03 2007-10-11 Korea Research Institute Of Bioscience And Biotechnology A novel monoclonal antibody specific to the l1cam, a hybridoma producing the same and a method producing the same
AU2007288620B2 (en) 2006-08-23 2012-08-30 Korea Research Instititute Of Bioscience And Biotechnology A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangiocarcinoma
WO2008151819A2 (en) * 2007-06-15 2008-12-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of tumors using specific anti-l1 antibody
AU2008201871A1 (en) * 2008-04-16 2009-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Inhibition of angiogenesis and tumor metastasis
KR20100060351A (ko) 2008-11-27 2010-06-07 한국생명공학연구원 L1cam의 활성 또는 발현을 억제하는 물질 및 항암제를포함하는 항암용 조성물
KR101504039B1 (ko) * 2012-11-16 2015-03-19 강원대학교산학협력단 인간 및 마우스 l1cam 단백질에 특이적으로 결합하는 항체 및 이의 용도
KR20250140647A (ko) * 2020-08-03 2025-09-25 난트셀, 인크. Il-15 초작용제에 대한 약물-특이적 약동학 검정

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939240A (en) * 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
GB2339200B (en) * 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
ES2296586T3 (es) * 2000-07-10 2008-05-01 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Metodo de diagnostico basado en la deteccion de la molecula de adhesion l1 para tumores de ovario y el endometrio.
US20020115065A1 (en) * 2000-08-28 2002-08-22 Ton Logtenberg Differentially expressed epitopes and uses thereof
EP1399850A2 (en) * 2001-02-21 2004-03-24 The Board of Regents of The University of Oklahoma Hla ligand database utilizing predictive algorithms and methods of making and using same

Also Published As

Publication number Publication date
US7670601B2 (en) 2010-03-02
CA2415364C (en) 2009-02-24
WO2002004952A2 (en) 2002-01-17
AU2001285820A1 (en) 2002-01-21
CA2415364A1 (en) 2002-01-17
JP5165827B2 (ja) 2013-03-21
EP1172654A1 (en) 2002-01-16
DE60036935D1 (de) 2007-12-13
US7618785B2 (en) 2009-11-17
EP1172654B1 (en) 2007-10-31
ES2296586T3 (es) 2008-05-01
JP2004513074A (ja) 2004-04-30
EP1386162A2 (en) 2004-02-04
CN1479871A (zh) 2004-03-03
ATE377192T1 (de) 2007-11-15
WO2002004952A3 (en) 2003-11-06
US20080138331A1 (en) 2008-06-12
US20040259084A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
DE69837529T2 (de) Proteinmarker für lungenkrebs und deren verwendung
EP0782709B1 (en) Detection of cancer
DE3588043T2 (de) Cytokeratin-tumormarkierer und test zu deren nachweis.
DE68912403T2 (de) Monoklonaler Antikörper, spezifisch für eine in transformierten Zellen exprimierte Fibronectin-Sequenz, Hybridoma, das diesen Antikörper erzeugt und Verwendung dieses monoklonalen Antikörpers zur Diagnose von Tumoren.
DE69434470T2 (de) Zellkernmatrixproteine
DE69132122T2 (de) Reinigung von cytokeratinfragmenten
EP0970378A2 (de) $i(IN VITRO)-VERFAHREN ZUM PROGNOSTIZIEREN DES KRANKHEITSVERLAUFS VON PATIENTEN MIT MAMMAKARZINOM UND/ODER ZUM DIAGNOSTIZIEREN EINES MAMMAKARZINOMS
WO2003048782A1 (de) Verfahren zur diagnose von sepsis unter bestimmung löslicher cytokeratinfragmente
DE3942999A1 (de) Verfahren zum nachweis von malignen erkrankungen
DE69024043T2 (de) Monoklonaler antikörper mit erkennungsspezifität für ein glykoprotein des globulären membran-mucin-antigens aus menschlichem milchfett.
DE3856004T2 (de) Verwendung von monoclonalen rezeptoren gegen oncoproteinen zur überwachung von krebstherapie
EP1214447A2 (de) Nachweis des pyruvatkinase-isoenzyms im stuhl
EP1172654B1 (en) Diagnostic method based on the detection of the L1 adhesion molecule for ovarian and endometrial tumors
DE69019410T2 (de) Retinoblastoma-Genprodukt-Antikörper und deren Verwendungen.
DE69635925T2 (de) Verfahren und Vorrichtung zum Beurteilen der metastatischen Tendenz von Tumoren
EP0193880B1 (de) Verfahren und Reagenz zur Bestimmung des Follikel stimulierenden Hormons sowie hierzu geeignete monoklonale Antikörper
US20070237760A1 (en) Detection and treatment of cancer
DE69735760T2 (de) Antikörper gegen menschliches lect2, zellen die diesen produzieren und verfahren und kit zu dessen bestimmung
EP0431567B1 (de) Verfahren zum Nachweis eines kleinzelligen Bronchial-Karzinoms
EP0193881B1 (de) Verfahren und Reagenz zur Bestimmung des luteinisierenden Hormons sowie hierzu geeignete monoklonale Antikörper
DE3879684T2 (de) Von protein ps2 abgeleitete peptide.
DE19739360C2 (de) Verfahren zur Diagnose von frühen Krebsvorstufen der Leber und Niere
CN100381820C (zh) 评价受试物质的毛发生长促进活性的方法和试剂盒
DE3838900A1 (de) Pyruvatkinase-isoenzym typ m2 (tumor m2-pk) spezifische antikoerper/verfahren zu deren herstellung und deren verwendung
Radosevich et al. Expression of ras oncogene p21 during human fetal development as determined by monoclonal antibodies RAP-5, Y13-259, and DWP

Legal Events

Date Code Title Description
8364 No opposition during term of opposition